within Pharmacolibrary.Drugs.ATC.G;

model G04BD12
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.29,
    Cl             = 0.000225,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.167,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0015283333333333334,
    Tlag           = 25.2,            
    Vdp             = 0.144,
    k12             = 45.6,
    k21             = 45.6
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G04BD12</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Mirabegron is a selective beta-3 adrenergic receptor agonist used for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is approved for use in many countries and is currently used in clinical therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters from healthy adult volunteers (both sexes) after oral administration.</p><h4>References</h4><ol><li><p>Deeks, ED (2018). Mirabegron: A Review in Overactive Bladder Syndrome. <i>Drugs</i> 78(8) 833–844. DOI:<a href=&quot;https://doi.org/10.1007/s40265-018-0924-4&quot;>10.1007/s40265-018-0924-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29869204/&quot;>https://pubmed.ncbi.nlm.nih.gov/29869204</a></p></li><li><p>Iitsuka, H, et al., &amp; Sawamoto, T (2015). Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects. <i>Clinical therapeutics</i> 37(5) 1031–1044. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2015.02.021&quot;>10.1016/j.clinthera.2015.02.021</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25791612/&quot;>https://pubmed.ncbi.nlm.nih.gov/25791612</a></p></li><li><p>Kashyap, M, &amp; Tyagi, P (2013). The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. <i>Expert opinion on drug metabolism &amp; toxicology</i> 9(5) 617–627. DOI:<a href=&quot;https://doi.org/10.1517/17425255.2013.786700&quot;>10.1517/17425255.2013.786700</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23550899/&quot;>https://pubmed.ncbi.nlm.nih.gov/23550899</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G04BD12;
